Himalaya Nutravedics IPO Analysis & Review

Quick Answers

What is the Himalaya Nutravedics IPO GMP today? The Himalaya Nutravedics IPO GMP is ₹0 as of 21/9/2026, 5:15:53 am. The IPO price band is ₹100 - ₹106. GMP represents an unofficial grey-market indication and does not guarantee the listing price.

When does Himalaya Nutravedics IPO open? The Himalaya Nutravedics IPO opens on 2026-09-22 and closes on 2026-09-24.

What is the Himalaya Nutravedics IPO subscription status? The overall subscription is 0x.

Key IPO Information

ViewIPO AI Analysis Score

The Himalaya Nutravedics IPO scored 61/100 (Moderate Risk) in our deep analysis.

Frequently Asked Questions

What business does Himalaya Nutravedics India Ltd operate?

Himalaya Nutravedics India Ltd manufactures, markets, and distributes Ayurvedic and nutraceutical formulations. It produces both classical and proprietary formulations under its own brand and performs third-party contract manufacturing for other companies.

What is the issue size and price range for the Himalaya Nutravedics IPO?

The IPO has a total issue size of ₹26.50 crore consisting entirely of fresh issue shares, with a price band set between ₹100 and ₹106 per share.

What are the key dates for the Himalaya Nutravedics IPO?

The IPO opens on September 22, 2026, and closes on September 24, 2026. Share allotment is scheduled for September 25, 2026, with tentative listing on September 29, 2026.

How will the IPO proceeds be utilized by the company?

The company intends to use ₹13.75 crore for capital expenditure requirements, ₹7.50 crore for branding, digital marketing, and sales expansion, and the remaining funds for general corporate purposes.

What are the key financial performance trends of Himalaya Nutravedics?

The company's revenue grew from ₹14.42 crore in FY24 to ₹21.00 crore in FY25 and ₹43.07 crore in FY26. Profit after tax increased from ₹0.43 crore to ₹2.23 crore and ₹7.39 crore over the same period.

What are the major risk factors associated with this IPO?

Key risks include persistent negative cash flows from operations (-₹3.83 Cr in FY26), trademark oppositions regarding the 'Himalaya Nutravedics' brand name, single-facility operational concentration in Hyderabad, and heavy customer/supplier concentration.

View IPO
View IPO
Home›India›Himalaya Nutravedics ()
Himalaya Nutravedics Logo

Himalaya NutravedicsNSE SME / BSE SME:

Analyzed by ViewIPO Financial Research Team
Ayurvedic & NutraceuticalsIndiaFiled 2026-09-22Listing 2026-09-29Size ₹26.56Cr
Lot Size 1200
Live GMP
₹0 (0%)
Check Allotment
Status Link

Is Himalaya Nutravedics IPO Good? Quick Verdict

Himalaya Nutravedics IPO scored 61/100 (Moderate Risk) in our deep analysis. The strongest pillar is Financial at 85/100, while Competition is the primary concern at 35/100. Himalaya Nutravedics India Ltd exhibits rapid top-line revenue and net profit growth, but faces severe cash flow drag, heavy supplier/customer concentration, and trademark disputes.

IPO Score
61/100
Moderate Risk

Quick Verdict

Strong revenue acceleration from ₹14.42 Cr in FY24 to ₹43.07 Cr in FY26 alongside significant net profit expansion.
Integrated manufacturing infrastructure in Hyderabad producing diverse dosage forms for own-brand and contract clients.
Persistent negative cash flows from operating activities (-₹3.83 Cr in FY26) driven by inventory and trade receivable lock-up.
High supplier (94.30% top 10) and customer concentration (81.24% top 10) without long-term contracts.
Key trademark applications for 'Himalaya Nutravedics' are actively opposed before the Registrar of Trademarks.

Company Snapshot

Revenue (TTM)
₹43.07Cr↑ 105.1% YoY
Profitability
PositiveNet Income ₹7.39Cr
Gross Margin
— 
Market Cap
—Pending Data
IPO Size
₹26.56Cr 
Industry
Ayurvedic & Nutraceuticals 
P/E Ratio
—Pending Data

Risk Breakdown

Governance
60
Moderate
Financial
85
Excellent
Valuation
50
Expensive
Competition
35
High Risk
Dilution
70
Moderate
Promoter / Mgmt
60
Moderate

AI Summary

Himalaya Nutravedics India Ltd is a Hyderabad-based manufacturer and distributor of Ayurvedic and nutraceutical formulations operating through both own-brand products and third-party contract manufacturing. The company experienced notable financial growth from FY24 to FY26, with revenue scaling to ₹43.07 crore and profit after tax rising to ₹7.39 crore. However, Himalaya Nutravedics India Ltd continues to generate negative operating cash flows due to working capital buildup, alongside significant reliance on a limited group of suppliers and customers. Additionally, ongoing legal opposition to its key trademark applications presents an operational risk to its brand equity.

Overall Verdict: Himalaya Nutravedics India Ltd exhibits rapid top-line revenue and net profit growth, but faces severe cash flow drag, heavy supplier/customer concentration, and trademark disputes.

Key Highlights

  • •Operates an integrated manufacturing facility in Cherlapally, Hyderabad, producing soft gel, hard gel, tablets, liquid orals, and medicated oils.
  • •Dual business model covering own-brand Ayurvedic and nutraceutical sales (51.14% of FY26 revenue) and third-party contract manufacturing.
  • •Revenue increased steeply from ₹14.42 Cr in FY24 to ₹21.00 Cr in FY25 and ₹43.07 Cr in FY26.
  • •Net profit surged from ₹0.43 Cr in FY24 to ₹2.23 Cr in FY25 and ₹7.39 Cr in FY26.
  • •Network supported by a 56-person sales and marketing force focused on practitioner detailing and continuing medical education.
  • •Net IPO proceeds of ₹26.50 Cr are dedicated to capital expenditures (₹13.75 Cr), branding/digital marketing (₹7.50 Cr), and general corporate purposes.

Financial Performance

Revenue (Annual)

↑ +105.1% YoY

INR in Crores

Net Income (Annual)

↑ +231.4% YoY

INR in Crores

Cash Flow vs Profit

↓ -175.5% YoY

INR in Crores

CF
NP

EBITDA vs PAT

EBITDA YoY

INR in Crores

EBITDA
PAT

IPO Timeline

IPO Opens2026-09-22
IPO Closes2026-09-24
Basis of Allotment2026-09-25
Refunds & Demat2026-09-26
Listing Date2026-09-29

Valuation Analysis

IPO Price₹100 - ₹106
Estimated Fair Value
Pending Data
Valuation Premium
Pending
vs Fair Value

IPO DNA

Growth
60
Governance
60
Profitability
85
Valuation
50
Competition
35
Execution
60

Pros vs Cons

Pros

  • Rapid revenue growth from ₹14.42 Cr in FY24 to ₹43.07 Cr in FY26, alongside expanding profit margins (PAT reaching ₹7.39 Cr).
  • Diversified dosage capabilities across soft gelatin capsules, hard gelatin capsules, tablets, liquid orals, and medicated oils.
  • Dual engine growth combining own-brand formulations with high-volume contract manufacturing.
  • Dedicated, stockist-driven distribution network backed by a 56-member field sales force targeting practitioner prescriptions.

Cons

  • Negative cash flows from operating activities for three consecutive fiscal years (-₹3.83 Cr in FY26) due to capital tied up in inventory and receivables.
  • Heavy reliance on top customers (81.24% of FY26 revenue) and top suppliers (94.30% of FY26 purchases) without long-term supply/offtake contracts.
  • Active trademark opposition against 'Himalaya Nutravedics' core brand name applications by third parties.
  • Geographic operational concentration risk steming from reliance on a single manufacturing unit in Cherlapally, Hyderabad.

Financial Health

Revenue Growth
High growth (₹14.42 Cr to ₹43.07 Cr over FY24-FY26) (Excellent)
Debt Level
Outstanding secured borrowings of ₹5.32 Cr as of August 2026 (Good)
Cash & Equivalents
Negative operating cash flow (-₹3.83 Cr in FY26) (Weak)

Institutional Signals

Anchor Investors
Undisclosed
VC Backing Tier
None Disclosed
Strategic Partners
Contract manufacturing partnerships with third-party healthcare brands

Himalaya Nutravedics IPO Reddit Pulse & Sentiment

Real-time Reddit discussions & retail sentiment

No Public Data Available

We couldn't find any significant public discussions or retail sentiment threads for this IPO at the moment.

Disclaimer: These are raw community discussions aggregated from public forums. The AI summary and Reddit comments do not constitute financial advice. Always conduct your own independent research.

Himalaya Nutravedics IPO — Frequently Asked Questions

Related IPO Reports

A-One Steels

A-One Steels

AONE
0/100
View Report
ArMee Infotech

ArMee Infotech

ARMEE
55/100
View Report
Varmora Granito

Varmora Granito

VARMORA
56/100
View Report
FX Multitech

FX Multitech

FXML
59/100
View Report
Vivekanand Cotspin

Vivekanand Cotspin

VIVEKANAND
55/100
View Report
View All Active & Upcoming IPOs View IPO Calendar

IPO Terminology Explained

Confused by terms like GMP, Kostak, or Subject to Sauda? Read our detailed guides in the IPO Glossary to understand the terminology before you invest.

Grey Market Premium (GMP)Subject to SaudaASBAOffer for Sale (OFS)
View Full Glossary

Source Citation: All financial data and risk metrics are derived from the official prospectus filed with the regulator (SEBI DRHP/RHP). ViewIPO algorithms process this public data for informational purposes. Not financial advice.

Want to analyze another IPO?

Search any stock, IPO, company, ticker or filing and get instant AI-powered analysis.

Frequently Asked Questions about Himalaya Nutravedics

What is the expected listing price of Himalaya Nutravedics?

The expected listing price depends on the live Grey Market Premium. Check the live GMP and expected listing price for Himalaya Nutravedics on our Live GMP Tracker.